LSB (LakeShore Biopharma Co) Debt-to-Equity : 0.61 (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co Debt-to-Equity?

LakeShore Biopharma Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $40.94 Mil. LakeShore Biopharma Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $11.15 Mil. LakeShore Biopharma Co's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $85.15 Mil. LakeShore Biopharma Co's debt to equity for the quarter that ended in Sep. 2024 was 0.61.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for LakeShore Biopharma Co's Debt-to-Equity or its related term are showing as below:

LSB' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.54 Med: 0.65 Max: 1
Current: 0.61

During the past 4 years, the highest Debt-to-Equity Ratio of LakeShore Biopharma Co was 1.00. The lowest was -0.54. And the median was 0.65.

LSB's Debt-to-Equity is ranked worse than
80.02% of 1016 companies
in the Biotechnology industry
Industry Median: 0.14 vs LSB: 0.61

LakeShore Biopharma Co Debt-to-Equity Historical Data

The historical data trend for LakeShore Biopharma Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LakeShore Biopharma Co Debt-to-Equity Chart

LakeShore Biopharma Co Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

Debt-to-Equity

-0.04

-0.54

0.69

0.73

LakeShore Biopharma Co Quarterly Data
	Mar21	Mar22	Jun22	Sep22	Mar23	Jun23	Sep23	Mar24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial				0.69	0.80	1.00	0.73	0.61

Competitive Comparison of LakeShore Biopharma Co's Debt-to-Equity

For the Biotechnology subindustry, LakeShore Biopharma Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LakeShore Biopharma Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where LakeShore Biopharma Co's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

LakeShore Biopharma Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

LakeShore Biopharma Co's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(44.949	+	13.993)	/	81.262
	=	0.73

LakeShore Biopharma Co's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(40.94	+	11.149)	/	85.153
	=	0.61

LakeShore Biopharma Co (NAS:LSB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

LakeShore Biopharma Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of LakeShore Biopharma Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

LakeShore Biopharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

H6Z0:Germany

Address

38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629

Website

https://www.lakeshorebio.com

LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.